Introduction {#sec1-1}
============

Gonorrhea is the second most common sexually transmitted infection (STI) spreading worldwide \[[@R1]-[@R2]\]. It is a serious public health problem causing severe secondary sequelae, including pelvic inflammatory disease, first-trimester miscarriages, ectopic pregnancy, and infertility. *N. gonorrhoeae* infection may facilitate HIV acquisition and transmission \[[@R3]-[@R5]\]. Having been treated successfully before, nowadays, gonorrhea is considered to be one of the challenging STI due to the extraordinary ability of *N. gonorrhea* to develop resistance to almost all antimicrobials \[[@R6]\].

In 2018, the annual data of the Centre of Medical Statistics of the Ministry of Health reported that the incidence of gonorrhea has decreased to 9.7/100.000 and 9.2/100.000 population of Ukraine and Ternopil, respectively, which was 2.8 and 2.5 times lower than reported in 2008. Many cases of gonorrhea are not registered officially, and the real prevalence remains unknown in Ukraine \[[@R7]\]. Conventional, microscopy, and culture, which are less sensitive compared with molecular tests, are used preferably to detect gonorrhea in Ukraine \[[@R8]\].

Studying the socio-demographic, epidemiological, clinical and laboratory diagnostics data of patients with gonorrhea could highlight the main issues in the management of *N. gonorrhea* infection at the Ternopil regional STI clinic in Ukraine in 2013-2018.

Material and Methods {#sec1-2}
====================

A retrospective single-center descriptive study was performed at a tertiary dermatology and venerology care center, Ternopil Regional STI Clinic, Ukraine, from July 2013 to August 2018. One-hundred-thirty-six adult patients with gonorrhea were enrolled after giving their written informed consent. All personal information used in the study was confidential, and patient\'s identification information was not disclosed. Patients and their sexual partners were managed according to the national guidelines. Diagnosis of gonorrhea, urogenital chlamydiosis, and trichomoniasis was made as it was previously described in the collaborative project \[[@R8], [@R9]\]. Urogenital smears were stained by methylene blue and Gram for microscopic detection of *Gardnerella vaginalis* and *Candida spp*. *Herpes simplex type* *2* was recognized by enzyme-linked immunosorbent assay for detection of specific IgG (Vitrotest HSV2-IgG reagent kit, Ramintek Ltd., Ukraine) and by microscopy using Romanovsky-Giemsa-stained smears. The syphilis status was determined by the reaction of microprecipitation using cardiolipin antigen (Public Joint-Stock Company "Pharmstandard-Biolik", Ukraine) and Wasserman reaction using cardiolipin antigen for the complement fixation reaction, dried complement and diagnostic hemolytic serum for the complement fixation reaction (Public Joint-Stock Company "Pharmstandard-Biolik", Ukraine).

The HIV-status was determined according to the European guidelines by using point-of-care tests - SD Bioline HIV ½ -3.0 (Standard Diagnostics, Inc., Korea) and Alere DetermineTM HIV-1/2 SET (Alere Medical Co., Ltd, Japan) \[[@R10]\]. Anogenital warts were diagnosed according to the 2012 European guidelines \[[@R11]\]. Molluscum contagiosum was diagnosed according to the guideline of the British Association for Sexual Health and HIV \[[@R12]\]. The medical records of all patients were reviewed to collect relevant epidemiological and clinical data.

Analysis {#sec1-2.1}
--------

The analyzed data referred to age, gender, residency, occupation, marital status, reported national/regional incidence of infection, history of STI, the onset of sexual activity, sexual behavior, time after the last sexual contact, number of sexual partners during the previous three months, sexual contacts examination, incubation period, number of days with symptoms before the first visit to the STI clinic, symptoms, clinical diagnosis, concomitant STI, the use of laboratory methods, syphilis and HIV status, microscopy results, treatment prescribed for gonorrhea at the clinic, and treatment outcomes. The 95% confidence interval (95% CI) was calculated using the exact binomial distribution method. P-value was displayed with a threshold at 0.05. All statistical analyses were conducted using the MedCalc Statistical Software version 18.11.3 (MedCalc Software bvba, Ostend, Belgium).

Ethical approval {#sec1-2.2}
----------------

The Bioethics Commission of I. Horbachevsky Ternopil National Medical University approved the study (Excerpts from Minutes No. 29, dated 20.05.2015).

Results {#sec1-3}
=======

All 136 patients with gonorrhea included 86.8 % males and 13.2 % females. The male-to-female ratio was 6.6:1. The mean age of patients was 29.4 years (range 16 - 80). The majority of patients were residents of Ukraine (94.9%), urban citizens (71%), and single (75.6%). Detailed socio-demographic characteristics are presented in [Table 1](#T1){ref-type="table"}.

###### 

Population characteristics of adult patients with gonorrhoea in Ternopil region of Ukraine, 2013-2018.

  Population characteristics   All            Male            Female          p-value                                                      
  ---------------------------- -------------- --------------- --------------- --------- ------ --------------- ---- ------ --------------- --------
  Age, years                   n=134                                                                                                       
  \< 25 years                  44             32.8            \[24.9-41.4\]   37        31.6   \[23.3-40.8\]   7    41.2   \[18.5-67.1\]   0.4326
  25-34years                   60             44.8            \[36.2-53.6\]   51        43.6   \[34.4-53\]     9    52.9   \[29.5-78.6\]   0.4729
  \> 34 years                  30             22.4            \[15.7-30.4\]   29        24.8   \[17.3-33.6\]   1    5.9    \[0.2-28.7\]    0.0819
  **Country of origin**        n=136          n=118           n=18                                                                         
  Ukraine                      129            94.9            \[59.9-76.1\]   111       94.1   \[88.2-97.6\]   18   100    \[81.5-100\]    0.2918
  Foreigner                    7              5.1             \[2.1-10.3\]    7         5.9    \[2.4-11.8\]    0    0      \[0-8.5\]       0.2918
  p-value                      \< 0.0001      \< 0.0001       NA                                                                           
  **Place of residence**       n=131          n=116           n=17                                                                         
  Urban                        93             71.0            \[62.4-78.6\]   81        69.8   \[60.6-78\]     14   82.4   \[56.6-96.2\]   0.2847
  Rural                        38             29.0            \[21.4-37.6\]   35        30.1   \[21.9-39.3\]   3    17.6   \[3.8-43.4\]    0.2881
  p-value                      \< 0.0001      \< 0.0001       0.0002                                                                       
  Occupation                   n=85           n=72            n=13                                                                         
  Students                     18             21.2            \[13.1-31.4\]   13        18.1   \[10-28.9\]     5    38.5   \[13.9-68.5\]   0.0998
  Employed                     12             14.1            \[7.5-23.3\]    10        13.9   \[6.9-24.1\]    2    15.4   \[1.9-5.5\]     0.8870
  Unemployed                   55             64.7            \[53.6-74.8\]   49        68.1   \[56.1-78.6\]   6    46.1   \[19.2-74.8\]   0.1288
  **Marital status**           n=131          n=113           n=18                                                                         
  Married                      32             24.4            \[17.3-32.7\]   27        23.9   \[16.4-32.8\]   5    27.8   \[9.7-3.5\]     0.7216
  Single                       99             75.6            \[67.3-82.7\]   86        63.7   \[54.1-72.5\]   13   72.2   \[46.5-90.3\]   0.4846
  **p-value**                  **\<0.0001**   **\< 0.0001**   **0.0086**                                                                   

Note: CI, confidence interval; NA, not applicable.

Most of the patients were heterosexuals (96.3%), and only 3.7% of patients reported themselves as men-who-have-sex-with-men (MSM). The majority of patients had occasional partners (62.1%). Most patients (75%) had 2 - 4 sexual partners during the last three months.

The total sexual-chain comprised 400 persons. Those included 136 studied patients with gonorrhea and 264 sexual partners in the previous three months period. Less than half of persons from the sexual-chain group were examined (41.3%), including 136 patients with gonorrhea (34%) and 29 sexual partners (7.3%). The majority of sexual partners (89%) were not examined. Gonorrhea was detected in 41.4% (12/29) of the examined sexual partners. The probability of *N. gonorrhea* transmission within the frame of the epidemiologic sexual chain was high (1:2.4).

Most of the patients (98.4%) reported Ukraine as being the country of gonorrhea acquisition, mostly specifying the Ternopil region in 92.9% of cases. Females reported the Ternopil region as an area of acquiring gonorrhea significantly more frequently than males (p=0.031).

Sixteen patients (13.9%) reported a history of previous STI, including gonorrhea (5.1%), chlamydiosis (3.7%), trichomoniasis (6.6%), and syphilis (1.5%). The detailed epidemiologic characteristics of patients with gonorrhea are presented in [Table 2](#T2){ref-type="table"}.

###### 

Epidemiological data of adult patients with gonorrhoea in the Ternopil region, Ukraine, 2013-2018.

  Patient\'s characteristics                                  All         Male        Female          p-value                                                      
  ----------------------------------------------------------- ----------- ----------- --------------- --------- ------ --------------- ---- ------ --------------- -----------
  Relationship to the source of last sexual contact           n=132       n=115       n=17                                                                         
  Occasional partner                                          82          62.1        \[53.3-70.4\]   101       87.8   \[80.4-93.2\]   8    47.1   \[23-72.2\]     \< 0.0001
  Constant partner                                            50          37.9        \[29.6-46.8\]   14        12.2   \[6.8-19.6\]    9    52.9   \[27.8-77\]     \< 0.0001
  p-value                                                     0.0071      \< 0.0001   0.7390                                                                       
  **Number of sexual partners during the last 3 months**      n=136       n=118       n=18                                                                         
  1                                                           34          25          \[18-33.1\]     25        21.2   \[14.2-29.7\]   9    50     \[26-74\]       0.0088
  2                                                           80          58.8        \[50-67.2\]     76        64.4   \[55.1-73\]     4    22.2   \[6.4-47.6\]    0.0007
  3                                                           18          13.2        \[8-20.1\]      15        12.7   \[7.3-20.1\]    3    16.7   \[3.6-41.5\]    0.6420
  4                                                           4           3           \[0.8-7.4\]     2         1.7    \[0.2-6\]       2    11.1   \[1.4-34.7\]    0.0286
  Sexual contact examination                                  n=264       n=230       n=34                                                                         
  Examined                                                    29          11          \[7.5-15.4\]    16        7      \[4.1-11.1\]    13   38.2   \[22.1-56.4\]   \< 0.0001
  Not examined                                                235         89          \[84.6-92.5\]   214       93     \[88.9-95.9\]   21   61.8   \[43.6-77.9\]   \< 0.0001
  p-value                                                     \< 0.0001   \< 0.0001   0.0534                                                                       
  Reported country of infection                               n=129       n=111       n=18                                                                         
  Ukraine                                                     127         98.4        \[94.6-99.8\]   109       98.2   \[93.7-99.8\]   18   100    \[81.5-100\]    0.5677
  Abroad                                                      2           1.6         \[0.2-5.4\]     2         1.8    \[0.2-6.4\]     0    0      \[0-8.5\]       0.5677
  p-value                                                     \< 0.0001   \< 0.0001   NA                                                                           
  Reported region of infection                                n=127       n=109       n=18                                                                         
  Ternopil                                                    118         92.9        \[87-96.7\]     100       78.7   \[69.8-86\]     18   100    \[81.5-100\]    0.0310
  Other regions of Ukraine (Kyiv, Rivne, Lviv, Sumy, Lutsk)   9           7.1         \[3.3-13\]      9         21.3   \[14-30.2\]     0    0      \[0-8.5\]       0.0310
  p-value                                                     \< 0.0001   \< 0.0001   NA                                                                           
  History of STI                                              n=115       n=97        n=18                                                                         
  Any STI previously                                          99          86.1        \[78.4-91.8\]   83        85.6   \[77-91.9\]     16   88.9   \[65.3-98.6\]   0.7112
  Reported STI history                                        16          13.9        \[8.2-21.6\]    14        14.4   \[8.1-23\]      2    11.1   \[1.4-34.7\]    0.7112
  p-value                                                     \< 0.0001   \< 0.0001   \< 0.0001                                                                    

Note: CI, confidence interval; MSM, men who have sex with men; STI, sexually transmitted infections; NG, *Neisseria gonorrhoeae*; CT, *Chlamydia trachomatis*; TV, *Trichomonas vaginalis*; NA, not applicable.

The mean incubation period of gonorrhea was 4.6 days (ranging from 1 to 9). The patients visited the STI clinic in 4.4 days (range: 1-7) after the first symptoms of gonorrhea. A total mean of the infectious period from the infectious sexual intercourse to the first clinic visit (start of treatment) was 9 days (range: 2-16). Males were symptomatic in 94.1% and females in 61.1% of cases. The most prevalent symptoms were urethral discharge (78.8%) in males and vaginal discharge (38.9%) in females. Non-specific symptoms were reported by 14.4% male and 22.2% female patients. Detailed clinical characteristics are shown in [Table 3](#T3){ref-type="table"}.

###### 

Clinical characteristics of adult patients with gonorrhoea in the Ternopil region, Ukraine, 2013-2018

  Patient\'s characteristics                                                                                                                                                           All            
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------- ------ ---------------
  Male symptoms                                                                                                                                                                        n=118          
  Urethral discharge                                                                                                                                                                   93      78.8   \[70.3-85.8\]
  Urethral burning sensation with urination                                                                                                                                            83      70.3   \[61.2-78.4\]
  Other (rash on genitalia: n=8; unpleasant smell: n=4; swelling and redness of the glans penis: n=2; lower abdominal pain: n=1; frequent urination: n=1; itching of the penis: n=1)   17      14.4   \[8.6-22.1\]
  Male clinical diagnosis                                                                                                                                                              n=118          
  Urethritis                                                                                                                                                                           112     95     \[89.4-98.2\]
  Balanitis                                                                                                                                                                            7       5.9    \[2.4-11.8\]
  Balanoposthitis                                                                                                                                                                      4       3.4    \[0.9-8.5\]
  Proctitis                                                                                                                                                                            1       0.8    \[0.02-4.6\]
  Female symptoms                                                                                                                                                                      n=18           
  Vaginal discharges                                                                                                                                                                   7       38.9   \[17.3-64.3\]
  Other (vaginal itching: n=1; rash on genitalia: n=1; discomfort during urination: n=1; unpleasant smell: n=1)                                                                        4       22.2   \[6.4-47.6\]
  Female clinical diagnosis                                                                                                                                                            n=18           
  Endocervicitis                                                                                                                                                                       13      72.2   \[46.5-90.3\]
  Colpitis                                                                                                                                                                             6       33.3   \[13.3-59\]
  Cervical erosion                                                                                                                                                                     3       16.7   \[3.6-41.5\]

Note: CI, confidence interval

Concurrent STIs were detected in 45.6% of patients, being represented by *T. vaginalis* in 39.7%, *C. trachomatis* in 2.2%, anogenital warts in 2.2%, *Gardnerella vaginalis* in 2.2%, *Herpes simplex type* *2* in 1.5%, molluscum contagiousum in 0.7%, and *Candida spp*. in 1.6% of cases. HIV testing was performed in 46.3% of patients, and a positive rate was found in 1.6% of cases. The rest of the patients (53.7%) refused to be tested for HIV. All patients were screened for syphilis, and 0.7% positive results were received.

*N. gonorrhoeae* isolates were obtained from the male urethra in 86% specimens, from the cervix in 13.2%, from the rectum of MSM in 0.7% of cases. No specimen was collected from the pharynx.

Ceftriaxone-based therapy was used for 83.8% of patients. Dual therapy was administered the most frequently, based on ceftriaxone combined with other antimicrobials (67%). Monotherapy by ceftriaxone 1 g was used in 16.8% of cases. Nevertheless, 16.2% of patients were not treated with ceftriaxone, receiving monotherapy instead with clarithromycin, doxycycline, benzylpenicillin, azithromycin, or ofloxacin. Recovery was detected in all patients who had follow-up visits (58.1%), but 41.9% of patients ignored their follow-up testing.

Discussion {#sec1-4}
==========

Gonorrhea is spreading worldwide, and its prevalence is rising, especially in well-developed countries, as proved by highly sensitive and specific modern laboratory methods for screening and diagnosis \[[@R1]-[@R2]\]. However, the incidence of gonorrhea has dropped down in Ukraine during the last decade \[[@R7]\]. Nowadays, the management of gonorrhea remains quite challenging \[[@R13]\]. Population, epidemiological, clinical, and diagnostic data were analyzed to reveal the main existing challenges of management of *N. gonorrhea* infection in Ukraine.

In our study, males were examined disproportionally more often than females, and the male to female ratio was 6.6:1. Dave and Tshokey et al. presented almost the same rate of gonorrhea in females \[[@R14]-[@R15]\], while Giomi B. et al. reported a higher level in males \[[@R16]\]. Our data suggest that a majority of potentially infected females probably have been missed.

Homosexually-acquired gonorrhea was only 3.7% of the total. Other authors reported a higher level of MSM (25.9 - 52%) and bisexuals (1%) in STI clinics \[[@R14],[@R16]\]. Our study supposes that patients in Ukraine have a stigma to inform about their sexual behavior.

According to our study, gonorrhea had been a local infection during 2013-2018, because most patients were residents and reported Ukraine and the Ternopil region as the geographical area where they acquired the infection. Giomi B. et al. reported that the same data was received in STI clinics in Italy in 2001 \[[@R16]\]. A significant level of antimicrobial resistance of *N. gonorrhoeae* has been reported in Europe as well as over the world \[[@R17]-[@R20]\]. Therefore, exporting of gonococcal infections in the future can not be excluded, including antimicrobial-resistant isolates of *N. gonorrhea*.

According to the European gonorrhea guidelines, all sexual contacts of patients with gonorrhea should be traced within at least the preceding two months of symptoms onset, and three months after the diagnosis \[[@R21]\]. Our study showed that only 11% of the sexual partners passed the medical examination, and gonorrhea was detected in 41.4% of partners, which indicates a high probability of *N. gonorrhea* transmission (1:2.4) within the frames of epidemiologic sexual chains. Worryingly, 89% of sexual contacts were not examined, guessing that almost a half could be infected with *N. gonorrhoeae*.

A mean infectious period from the infectious sexual intercourse to the first visit at the clinic before the patients were diagnosed and started treatment was comparatively long (2-16 days). This fact may facilitate a transferring of gonococcal infection. Worryingly, this also could provoke a self-treatment because antimicrobials are over-the-counter drugs in Ukraine and available even through electronic marketing.

Asymptomatic gonorrhea was found in 5.9% males, and 38.9% of females and non-specific symptoms were expressed in 14.4% and 22.2% of cases, respectively. Asymptomatic patients could remain the hidden source of *N. gonorrhea* transmission, mainly if low sensitivity laboratory tests are used for screening and detection, i.e., microscopy and culture \[[@R8], [@R21]\].

Extragenital samples were taken extremely rare, as only one rectal sample was registered in this study. Information on oral-genital intercourses was not gathered, and pharyngeal samples were not collected in this study. This indicates a present stigma in patients to inform about the type of sexual intercourse and sexual behavior. Therefore, clinicians should collect more detailed sexual history and take extragenital samples, especially pharyngeal, that are considered to be hidden sites of *N. gonorrhea*, where antimicrobial resistance may develop \[[@R21]\].

The most prevalent concurrent STI infection among patients with gonorrhea is *C. trachomatis* \[[@R2]\]. A comparatively low rate of chlamydial infection (2.2%) was registered by using conventional laboratory tests (microscopy by Romanovsky-Giemsa and serology by ELISA), indicating a crucial underdiagnosis of *C. trachomatis* \[[@R8]\]. The highly effective molecular test is urgently needed to be implemented into the routine STI diagnostic in Ukraine, as well it is used in most countries worldwide \[[@R23]-[@R25]\].

A significant part of studied patients had a high level of concomitant *T. vaginalis* (39.7%) detected by microscopy. Previously, we described suboptimal performance characteristics for methylene blue and Gram-stained microscopy \[[@R8]\]. The present study confirmed that highly specific, sensitive, and quality assured molecular tests are needed for routine STI diagnostic in Ukraine.

Worryingly, 53.7% of observed patients were not tested for HIV, as it was the same reported in other studies \[[@R26]\]. Li et al. suggest that a high level of HIV infection is present in patients with STI and particularly with gonorrhea \[[@R27]\]. Our study highlighted that improving HIV counseling is needed among patients with gonorrhea in Ukraine.

Nevertheless, the concurrent syphilis was detected in 0.7% of patients with gonorrhea; the real level of *T. pallidum* infection is supposed to be underestimated because of using non-treponemal tests during screening \[[@R28], [@R29]\]. Accordingly, a highly sensitive and quality assured syphilis serology tests are imperative in Ukraine.

A significant part of patients (41.9%) who missed their follow-up visits could form a reservoir of persistent infection and be a source of further transmission of *N. gonorrhea*.

Some patients (16.2%) received questionable treatment using monotherapy with clarithromycin, doxycycline, benzylpenicillin, azithromycin, or ofloxacin \[[@R21]\]. Ukrainian gonorrhea treatment guidelines were not updated since 2009. It is essential to make further improvement of treatment based on the European gonorrhea guidelines or adapted national evidence-based guidelines \[[@R9], [@R21], [@R23], [@R24]\].

An issue of social stigma associated with gonorrhea was raised previously \[[@R1], [@R15]\]. Our study supposed that gonococcal infection is stigmatized in Ukraine as well because of low levels of (a) reporting homosexual behavior, (b) willing to be screened for HIV, (c) compliance to have follow-up visits, and sporadically collection of extragenital samples by clinicians.

Conclusions {#sec1-5}
===========

The key challenges of the management of *N. gonorrhoeae* infection in Ukraine are the low level of examined females, asymptomatic infection in patients and sexual partners; disregarded testing of extragenital specimens, using of conventional laboratory tests (microscopy and culture) for screening and diagnostics of gonorrhea; deficient access to nucleic acid amplification tests in the public leading specialised STI clinics in Ukraine, low level of screening for HIV; low compliance of the follow-up visits; receiving questionable or even obsolete antimicrobial treatment. It is also supposed by our data that gonococcal infection is stigmatised. Therefore, more accurate and comprehensive management of gonorrhoea is urgently needed in Ukraine.
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